Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Recombinant Herpes Zoster Vaccine in Healthy Adults

NCT06801509 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT06801509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06801509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Recombinant Herpes Zoster Vaccine in Healthy Adults
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
February 15, 2025
Completion date
October 10, 2027
Enrollment
540 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster